Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2007-12

AUTHORS

Michael A Morse, Amy Hobeika, Takuya Osada, Donna Niedzwiecki, Paul Kelly Marcom, Kimberly L Blackwell, Carey Anders, Gayathri R Devi, H Kim Lyerly, Timothy M Clay

ABSTRACT

BACKGROUND: The HER2-inhibiting antibody trastuzumab, in combination with chemotherapy, significantly improves survival of women with resected, HER2-overexpressing breast cancers, but is associated with toxicities including a risk of cardiomyopathy. Additionally, the beneficial effect of trastuzumab is expected to decrease once the drug is discontinued. We proposed to address these concerns by using cancer vaccines to stimulate HER2 intracellular domain (ICD)-specific T cell and antibody responses. METHODS: Subjects with stage II (> or = 6 +LN), III, or stage IV breast cancer with > 50% HER2 overexpressing tumor cells who were disease-free after surgery and adjuvant therapy were eligible. Vaccines consisted of immature, cultured DC (n = 3), mature cultured DC (n = 3), or mature Flt3-ligand mobilized peripheral blood DC (n = 1) loaded with ICD, or tetanus toxoid, keyhole limpet hemocyanin or CMV peptide as controls, and were administered intradermally/subcutaneously four times at 3 week intervals. ICD-specific T cell and antibody responses were measured. Cardiac function was determined by MUGA or ECHO; long term disease status was obtained from patient contact. RESULTS: All seven patients successfully underwent DC generation and five received all 4 immunizations. There were no toxicities greater than grade 1 or ejection fraction decrements below normal. Delayed-type hypersensitivity (DTH) reactions at the injection site occurred in 6/7 patients and HER2 specificity was detected by cytokine flow cytometry or ELISPOT in 5 patients. At more than 5 years of follow-up, 6/7 had detectable anti-ICD antibodies. One patient experienced a pulmonary recurrence at 4 years from their study immunizations. This recurrence was resected and they are without evidence of disease. All patients are alive and disease-free at 4.6-6.7 years of follow-up. CONCLUSION: Although this was a small pilot study, the well-tolerated nature of the vaccines, the lack of cardiac toxicity, significant immunogenicity, and a 100% 4.5-year survival rate suggest that vaccination with HER2 ICD protein-containing DC is appropriate for further study in this population. TRIAL REGISTRATION: ClinicalTrials.gov NCT00005956. More... »

PAGES

42

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1479-5876-5-42

DOI

http://dx.doi.org/10.1186/1479-5876-5-42

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1019767882

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17822557


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibody Formation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CD4-Positive T-Lymphocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CD8-Positive T-Lymphocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cancer Vaccines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Confidence Intervals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme-Linked Immunosorbent Assay", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypersensitivity, Delayed", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-gamma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intracellular Space", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Structure, Tertiary", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "T-Lymphocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vaccination", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3233, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morse", 
        "givenName": "Michael A", 
        "id": "sg:person.013700705377.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013700705377.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Surgery, Duke University Medical Center, Box 2606, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hobeika", 
        "givenName": "Amy", 
        "id": "sg:person.07741424047.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07741424047.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Surgery, Duke University Medical Center, Box 2606, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Osada", 
        "givenName": "Takuya", 
        "id": "sg:person.01114717615.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114717615.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.414179.e", 
          "name": [
            "Department of Biostatistics & Bioinformatics, Duke University Medical Center, Box 3958, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Niedzwiecki", 
        "givenName": "Donna", 
        "id": "sg:person.0761643572.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761643572.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3147, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marcom", 
        "givenName": "Paul Kelly", 
        "id": "sg:person.0743757323.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743757323.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3893, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blackwell", 
        "givenName": "Kimberly L", 
        "id": "sg:person.01264356120.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264356120.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3233, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Anders", 
        "givenName": "Carey", 
        "id": "sg:person.01176312760.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176312760.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Surgery, Duke University Medical Center, Box 2606, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Devi", 
        "givenName": "Gayathri R", 
        "id": "sg:person.01023745630.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023745630.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University", 
          "id": "https://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Department of Surgery, Duke University Medical Center, Box 2606, 27710, Durham, NC, USA", 
            "Duke Comprehensive Cancer Center (DCCC), Duke University Medical Center, 6th Floor Hock Plaza, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lyerly", 
        "givenName": "H Kim", 
        "id": "sg:person.012507420117.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012507420117.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Surgery, Division of Experimental Surgery, Duke University Medical Center, Box 2606, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clay", 
        "givenName": "Timothy M", 
        "id": "sg:person.0706420433.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706420433.90"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0092-8674(01)00449-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008090278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.immunol.19.1.47", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008840820"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.09.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012109705"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10875-005-8216-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025200602", 
          "https://doi.org/10.1007/s10875-005-8216-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10875-005-8216-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025200602", 
          "https://doi.org/10.1007/s10875-005-8216-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/cbc.2003.s.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025570019"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.03.047", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026768698"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa052122", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035589584"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa052122", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035589584"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood.v99.8.2845", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043929611"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1677/erc.1.00671", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052544975"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00262-004-0520-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053288287", 
          "https://doi.org/10.1007/s00262-004-0520-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.06.171", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074485263", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074628583", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4049/jimmunol.165.1.566", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074656412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075050984", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075189858", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076607157", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1990.8.1.103", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077944782"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082558391", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.11.3363", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083171126"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-12", 
    "datePublishedReg": "2007-12-01", 
    "description": "BACKGROUND: The HER2-inhibiting antibody trastuzumab, in combination with chemotherapy, significantly improves survival of women with resected, HER2-overexpressing breast cancers, but is associated with toxicities including a risk of cardiomyopathy. Additionally, the beneficial effect of trastuzumab is expected to decrease once the drug is discontinued. We proposed to address these concerns by using cancer vaccines to stimulate HER2 intracellular domain (ICD)-specific T cell and antibody responses.\nMETHODS: Subjects with stage II (> or = 6 +LN), III, or stage IV breast cancer with > 50% HER2 overexpressing tumor cells who were disease-free after surgery and adjuvant therapy were eligible. Vaccines consisted of immature, cultured DC (n = 3), mature cultured DC (n = 3), or mature Flt3-ligand mobilized peripheral blood DC (n = 1) loaded with ICD, or tetanus toxoid, keyhole limpet hemocyanin or CMV peptide as controls, and were administered intradermally/subcutaneously four times at 3 week intervals. ICD-specific T cell and antibody responses were measured. Cardiac function was determined by MUGA or ECHO; long term disease status was obtained from patient contact.\nRESULTS: All seven patients successfully underwent DC generation and five received all 4 immunizations. There were no toxicities greater than grade 1 or ejection fraction decrements below normal. Delayed-type hypersensitivity (DTH) reactions at the injection site occurred in 6/7 patients and HER2 specificity was detected by cytokine flow cytometry or ELISPOT in 5 patients. At more than 5 years of follow-up, 6/7 had detectable anti-ICD antibodies. One patient experienced a pulmonary recurrence at 4 years from their study immunizations. This recurrence was resected and they are without evidence of disease. All patients are alive and disease-free at 4.6-6.7 years of follow-up.\nCONCLUSION: Although this was a small pilot study, the well-tolerated nature of the vaccines, the lack of cardiac toxicity, significant immunogenicity, and a 100% 4.5-year survival rate suggest that vaccination with HER2 ICD protein-containing DC is appropriate for further study in this population.\nTRIAL REGISTRATION: ClinicalTrials.gov NCT00005956.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1479-5876-5-42", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1032886", 
        "issn": [
          "1479-5876"
        ], 
        "name": "Journal of Translational Medicine", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "name": "Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2", 
    "pagination": "42", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "5e2f9733d80c533b6c0fd443484d3784a4d8b00f34bec6c5d98b623e02400aee"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17822557"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101190741"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1479-5876-5-42"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1019767882"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1479-5876-5-42", 
      "https://app.dimensions.ai/details/publication/pub.1019767882"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:09", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8660_00000512.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1479-5876-5-42"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-5-42'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-5-42'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-5-42'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-5-42'


 

This table displays all metadata directly associated to this object as RDF triples.

286 TRIPLES      21 PREDICATES      71 URIs      43 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1479-5876-5-42 schema:about N17030bd69c634897b5deddb0b2dcfe51
2 N21b2ea5cb01a4b63906d52297bde3619
3 N32a19021f7ad4dafb887f144dc5e1f38
4 N35ad5606a51c40b9a53461be74c14dc3
5 N3929788ada514f79940e84d503ee0cbf
6 N39e30a272ad048ba92a6f091cc1cea22
7 N40656386278d4ea792e53b193f448ac6
8 N47966da6886b4706bab07c7e1d93c5d7
9 N4b9442d8aa7e4605bcf7a8ca7c36f478
10 N5690ca2f67f7428dbab3209f2649b612
11 N6e00aad5c2bd402d9a27320c0c303643
12 N747ea6470983477ea923531f55333163
13 N877c01811a064166807ddf8cca08a207
14 N8b54eecee85240e4b69d8ef2f091a278
15 N97c98516942748bcbda4a42be22cda92
16 N9b59cd6c614b42df9627231dc0e67d58
17 Nada451b85d374368ab3ae3ee190d1e89
18 Nb1704e684b40418ab2e55da682c5c20e
19 Nc8ceafe5cde64da6ac936205c00ae1a1
20 Nd5f1c6edcfed454cbdb2828dd457bf4f
21 Nd7438bfd2c0e45aebb649aa41d32baae
22 Nf2d1a3674d914bc0bdecd1fb09c3c3fa
23 anzsrc-for:11
24 anzsrc-for:1112
25 schema:author N3c3deadf1bcf465991167a7a293e81b3
26 schema:citation sg:pub.10.1007/s00262-004-0520-1
27 sg:pub.10.1007/s10875-005-8216-7
28 https://app.dimensions.ai/details/publication/pub.1074485263
29 https://app.dimensions.ai/details/publication/pub.1074628583
30 https://app.dimensions.ai/details/publication/pub.1075050984
31 https://app.dimensions.ai/details/publication/pub.1075189858
32 https://app.dimensions.ai/details/publication/pub.1076607157
33 https://app.dimensions.ai/details/publication/pub.1082558391
34 https://doi.org/10.1016/s0092-8674(01)00449-4
35 https://doi.org/10.1056/nejmoa052122
36 https://doi.org/10.1146/annurev.immunol.19.1.47
37 https://doi.org/10.1182/blood.v99.8.2845
38 https://doi.org/10.1200/jco.1990.8.1.103
39 https://doi.org/10.1200/jco.1997.15.11.3363
40 https://doi.org/10.1200/jco.2002.06.171
41 https://doi.org/10.1200/jco.2004.09.005
42 https://doi.org/10.1200/jco.2005.03.047
43 https://doi.org/10.1677/erc.1.00671
44 https://doi.org/10.3816/cbc.2003.s.007
45 https://doi.org/10.4049/jimmunol.165.1.566
46 schema:datePublished 2007-12
47 schema:datePublishedReg 2007-12-01
48 schema:description BACKGROUND: The HER2-inhibiting antibody trastuzumab, in combination with chemotherapy, significantly improves survival of women with resected, HER2-overexpressing breast cancers, but is associated with toxicities including a risk of cardiomyopathy. Additionally, the beneficial effect of trastuzumab is expected to decrease once the drug is discontinued. We proposed to address these concerns by using cancer vaccines to stimulate HER2 intracellular domain (ICD)-specific T cell and antibody responses. METHODS: Subjects with stage II (> or = 6 +LN), III, or stage IV breast cancer with > 50% HER2 overexpressing tumor cells who were disease-free after surgery and adjuvant therapy were eligible. Vaccines consisted of immature, cultured DC (n = 3), mature cultured DC (n = 3), or mature Flt3-ligand mobilized peripheral blood DC (n = 1) loaded with ICD, or tetanus toxoid, keyhole limpet hemocyanin or CMV peptide as controls, and were administered intradermally/subcutaneously four times at 3 week intervals. ICD-specific T cell and antibody responses were measured. Cardiac function was determined by MUGA or ECHO; long term disease status was obtained from patient contact. RESULTS: All seven patients successfully underwent DC generation and five received all 4 immunizations. There were no toxicities greater than grade 1 or ejection fraction decrements below normal. Delayed-type hypersensitivity (DTH) reactions at the injection site occurred in 6/7 patients and HER2 specificity was detected by cytokine flow cytometry or ELISPOT in 5 patients. At more than 5 years of follow-up, 6/7 had detectable anti-ICD antibodies. One patient experienced a pulmonary recurrence at 4 years from their study immunizations. This recurrence was resected and they are without evidence of disease. All patients are alive and disease-free at 4.6-6.7 years of follow-up. CONCLUSION: Although this was a small pilot study, the well-tolerated nature of the vaccines, the lack of cardiac toxicity, significant immunogenicity, and a 100% 4.5-year survival rate suggest that vaccination with HER2 ICD protein-containing DC is appropriate for further study in this population. TRIAL REGISTRATION: ClinicalTrials.gov NCT00005956.
49 schema:genre research_article
50 schema:inLanguage en
51 schema:isAccessibleForFree true
52 schema:isPartOf N213d33c9315f4565b7f26d46073df86d
53 Nc63d85f890cf492ab9873bde3f4bb4ff
54 sg:journal.1032886
55 schema:name Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
56 schema:pagination 42
57 schema:productId N11696e16272444ea858c4c3b95a68a65
58 N35efadf8ae674fa9a44ef24d134927fe
59 N88a220abd13748c4860f71b12295908e
60 N96c984447dd6462aa1d69516d1704a37
61 Nc7a44b4f303e4a4dad086dfd4265573c
62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019767882
63 https://doi.org/10.1186/1479-5876-5-42
64 schema:sdDatePublished 2019-04-10T14:09
65 schema:sdLicense https://scigraph.springernature.com/explorer/license/
66 schema:sdPublisher N5854abd9f5f84d13819b803453412a10
67 schema:url http://link.springer.com/10.1186%2F1479-5876-5-42
68 sgo:license sg:explorer/license/
69 sgo:sdDataset articles
70 rdf:type schema:ScholarlyArticle
71 N0b6ab5e20e404892aa0cc7afcb1c5a0f rdf:first sg:person.07741424047.51
72 rdf:rest N316ce9d3b860480ca46c50d97c120e42
73 N11696e16272444ea858c4c3b95a68a65 schema:name pubmed_id
74 schema:value 17822557
75 rdf:type schema:PropertyValue
76 N16496a45e23b445eb87ed93ffb4d5c65 rdf:first sg:person.0743757323.50
77 rdf:rest N5e158e0e7fba4409aa1786353236da5f
78 N17030bd69c634897b5deddb0b2dcfe51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Protein Structure, Tertiary
80 rdf:type schema:DefinedTerm
81 N213d33c9315f4565b7f26d46073df86d schema:volumeNumber 5
82 rdf:type schema:PublicationVolume
83 N21b2ea5cb01a4b63906d52297bde3619 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Receptor, ErbB-2
85 rdf:type schema:DefinedTerm
86 N316ce9d3b860480ca46c50d97c120e42 rdf:first sg:person.01114717615.49
87 rdf:rest Nfb27f308a30b475baafaa5a1d9e5dde1
88 N32a19021f7ad4dafb887f144dc5e1f38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Vaccination
90 rdf:type schema:DefinedTerm
91 N35ad5606a51c40b9a53461be74c14dc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Antigens, Neoplasm
93 rdf:type schema:DefinedTerm
94 N35efadf8ae674fa9a44ef24d134927fe schema:name dimensions_id
95 schema:value pub.1019767882
96 rdf:type schema:PropertyValue
97 N3929788ada514f79940e84d503ee0cbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Disease-Free Survival
99 rdf:type schema:DefinedTerm
100 N39e30a272ad048ba92a6f091cc1cea22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Enzyme-Linked Immunosorbent Assay
102 rdf:type schema:DefinedTerm
103 N3c3deadf1bcf465991167a7a293e81b3 rdf:first sg:person.013700705377.06
104 rdf:rest N0b6ab5e20e404892aa0cc7afcb1c5a0f
105 N40656386278d4ea792e53b193f448ac6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Interferon-gamma
107 rdf:type schema:DefinedTerm
108 N47966da6886b4706bab07c7e1d93c5d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Cancer Vaccines
110 rdf:type schema:DefinedTerm
111 N4b9442d8aa7e4605bcf7a8ca7c36f478 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Time Factors
113 rdf:type schema:DefinedTerm
114 N5690ca2f67f7428dbab3209f2649b612 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Kaplan-Meier Estimate
116 rdf:type schema:DefinedTerm
117 N5854abd9f5f84d13819b803453412a10 schema:name Springer Nature - SN SciGraph project
118 rdf:type schema:Organization
119 N5e158e0e7fba4409aa1786353236da5f rdf:first sg:person.01264356120.90
120 rdf:rest Nbd3f73ec35014bd9be4f6b063b15407f
121 N6e00aad5c2bd402d9a27320c0c303643 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Breast Neoplasms
123 rdf:type schema:DefinedTerm
124 N719c26f9c9874f9ebfe4843a185d2f88 rdf:first sg:person.01023745630.53
125 rdf:rest N80bc92e347064b1ab22f992b0f0e8238
126 N747ea6470983477ea923531f55333163 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Antibody Formation
128 rdf:type schema:DefinedTerm
129 N80bc92e347064b1ab22f992b0f0e8238 rdf:first sg:person.012507420117.48
130 rdf:rest Ncaa5631ec4244df4a57060ca30557d78
131 N877c01811a064166807ddf8cca08a207 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name T-Lymphocytes
133 rdf:type schema:DefinedTerm
134 N88a220abd13748c4860f71b12295908e schema:name readcube_id
135 schema:value 5e2f9733d80c533b6c0fd443484d3784a4d8b00f34bec6c5d98b623e02400aee
136 rdf:type schema:PropertyValue
137 N8b54eecee85240e4b69d8ef2f091a278 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Humans
139 rdf:type schema:DefinedTerm
140 N96c984447dd6462aa1d69516d1704a37 schema:name doi
141 schema:value 10.1186/1479-5876-5-42
142 rdf:type schema:PropertyValue
143 N97c98516942748bcbda4a42be22cda92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Confidence Intervals
145 rdf:type schema:DefinedTerm
146 N9b59cd6c614b42df9627231dc0e67d58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name CD8-Positive T-Lymphocytes
148 rdf:type schema:DefinedTerm
149 Nada451b85d374368ab3ae3ee190d1e89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Middle Aged
151 rdf:type schema:DefinedTerm
152 Nb1704e684b40418ab2e55da682c5c20e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Adult
154 rdf:type schema:DefinedTerm
155 Nbd3f73ec35014bd9be4f6b063b15407f rdf:first sg:person.01176312760.26
156 rdf:rest N719c26f9c9874f9ebfe4843a185d2f88
157 Nc63d85f890cf492ab9873bde3f4bb4ff schema:issueNumber 1
158 rdf:type schema:PublicationIssue
159 Nc7a44b4f303e4a4dad086dfd4265573c schema:name nlm_unique_id
160 schema:value 101190741
161 rdf:type schema:PropertyValue
162 Nc8ceafe5cde64da6ac936205c00ae1a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name CD4-Positive T-Lymphocytes
164 rdf:type schema:DefinedTerm
165 Ncaa5631ec4244df4a57060ca30557d78 rdf:first sg:person.0706420433.90
166 rdf:rest rdf:nil
167 Nd5f1c6edcfed454cbdb2828dd457bf4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Hypersensitivity, Delayed
169 rdf:type schema:DefinedTerm
170 Nd7438bfd2c0e45aebb649aa41d32baae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Intracellular Space
172 rdf:type schema:DefinedTerm
173 Nf2d1a3674d914bc0bdecd1fb09c3c3fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Female
175 rdf:type schema:DefinedTerm
176 Nfb27f308a30b475baafaa5a1d9e5dde1 rdf:first sg:person.0761643572.59
177 rdf:rest N16496a45e23b445eb87ed93ffb4d5c65
178 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
179 schema:name Medical and Health Sciences
180 rdf:type schema:DefinedTerm
181 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
182 schema:name Oncology and Carcinogenesis
183 rdf:type schema:DefinedTerm
184 sg:journal.1032886 schema:issn 1479-5876
185 schema:name Journal of Translational Medicine
186 rdf:type schema:Periodical
187 sg:person.01023745630.53 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
188 schema:familyName Devi
189 schema:givenName Gayathri R
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023745630.53
191 rdf:type schema:Person
192 sg:person.01114717615.49 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
193 schema:familyName Osada
194 schema:givenName Takuya
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114717615.49
196 rdf:type schema:Person
197 sg:person.01176312760.26 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
198 schema:familyName Anders
199 schema:givenName Carey
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176312760.26
201 rdf:type schema:Person
202 sg:person.012507420117.48 schema:affiliation https://www.grid.ac/institutes/grid.26009.3d
203 schema:familyName Lyerly
204 schema:givenName H Kim
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012507420117.48
206 rdf:type schema:Person
207 sg:person.01264356120.90 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
208 schema:familyName Blackwell
209 schema:givenName Kimberly L
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264356120.90
211 rdf:type schema:Person
212 sg:person.013700705377.06 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
213 schema:familyName Morse
214 schema:givenName Michael A
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013700705377.06
216 rdf:type schema:Person
217 sg:person.0706420433.90 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
218 schema:familyName Clay
219 schema:givenName Timothy M
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706420433.90
221 rdf:type schema:Person
222 sg:person.0743757323.50 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
223 schema:familyName Marcom
224 schema:givenName Paul Kelly
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743757323.50
226 rdf:type schema:Person
227 sg:person.0761643572.59 schema:affiliation https://www.grid.ac/institutes/grid.414179.e
228 schema:familyName Niedzwiecki
229 schema:givenName Donna
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761643572.59
231 rdf:type schema:Person
232 sg:person.07741424047.51 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
233 schema:familyName Hobeika
234 schema:givenName Amy
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07741424047.51
236 rdf:type schema:Person
237 sg:pub.10.1007/s00262-004-0520-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053288287
238 https://doi.org/10.1007/s00262-004-0520-1
239 rdf:type schema:CreativeWork
240 sg:pub.10.1007/s10875-005-8216-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025200602
241 https://doi.org/10.1007/s10875-005-8216-7
242 rdf:type schema:CreativeWork
243 https://app.dimensions.ai/details/publication/pub.1074485263 schema:CreativeWork
244 https://app.dimensions.ai/details/publication/pub.1074628583 schema:CreativeWork
245 https://app.dimensions.ai/details/publication/pub.1075050984 schema:CreativeWork
246 https://app.dimensions.ai/details/publication/pub.1075189858 schema:CreativeWork
247 https://app.dimensions.ai/details/publication/pub.1076607157 schema:CreativeWork
248 https://app.dimensions.ai/details/publication/pub.1082558391 schema:CreativeWork
249 https://doi.org/10.1016/s0092-8674(01)00449-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008090278
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1056/nejmoa052122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035589584
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1146/annurev.immunol.19.1.47 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008840820
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1182/blood.v99.8.2845 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043929611
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1200/jco.1990.8.1.103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077944782
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1200/jco.1997.15.11.3363 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083171126
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1200/jco.2002.06.171 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203009
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1200/jco.2004.09.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012109705
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1200/jco.2005.03.047 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026768698
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1677/erc.1.00671 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052544975
268 rdf:type schema:CreativeWork
269 https://doi.org/10.3816/cbc.2003.s.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025570019
270 rdf:type schema:CreativeWork
271 https://doi.org/10.4049/jimmunol.165.1.566 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074656412
272 rdf:type schema:CreativeWork
273 https://www.grid.ac/institutes/grid.189509.c schema:alternateName Duke University Hospital
274 schema:name Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3147, 27710, Durham, NC, USA
275 Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3233, 27710, Durham, NC, USA
276 Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3893, 27710, Durham, NC, USA
277 Department of Surgery, Division of Experimental Surgery, Duke University Medical Center, Box 2606, 27710, Durham, NC, USA
278 Department of Surgery, Duke University Medical Center, Box 2606, 27710, Durham, NC, USA
279 rdf:type schema:Organization
280 https://www.grid.ac/institutes/grid.26009.3d schema:alternateName Duke University
281 schema:name Department of Surgery, Duke University Medical Center, Box 2606, 27710, Durham, NC, USA
282 Duke Comprehensive Cancer Center (DCCC), Duke University Medical Center, 6th Floor Hock Plaza, 27710, Durham, NC, USA
283 rdf:type schema:Organization
284 https://www.grid.ac/institutes/grid.414179.e schema:alternateName Duke Medical Center
285 schema:name Department of Biostatistics & Bioinformatics, Duke University Medical Center, Box 3958, 27710, Durham, NC, USA
286 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...